The FDA moved to lock in stability for drug and biologics oversight by appointing Michael Davis as permanent director of CDER and Karim Mikhail as permanent director of CBER, ending their acting tenures. The change follows a turbulent period that unsettled industry leaders and investors, and comes as the agency awaits a commissioner nomination confirmation. In parallel, the administration created a new FDA deputy role focused on technology and artificial intelligence, signaling continued emphasis on leveraging AI in review workflows. Analysts characterized the director appointments as a “continuity and stability” signal meant to reduce expectations of major policy pivots during the transition. For biotech companies, the immediate impact is regulatory predictability: division heads typically guide decision-making on complex review issues, including novel modalities and expedited pathways. A more settled leadership structure may also affect timelines for advisory interactions and execution of internal operational changes. The appointments arrive as broader scrutiny of FDA decision-making has increased, placing a premium on consistent, well-communicated standards for sponsors operating across late-stage and lifecycle submission programs.